Aristides Capital’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Aristides Capital’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-70,000	Closed	-$1.62M	–	207
2020 Q4	$1.62M	Buy	+70,000	New	+$887K	0.55%	33

Aristides Capital's PRVL Position: Q1 2021 in Review

Aristides Capital sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 70,000 shares — an estimated $1.62M sold.

Aristides Capital first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $1.62M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Aristides Capital reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Aristides Capital sold 70,000 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $1.62M.
Aristides Capital first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Aristides Capital's Prevail Therapeutics Inc. Common Stock position peaked at $1.62M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Aristides Capital's 13F filing for Q1 2021, filed 17 May 2021.